Why the study?
Cancer therapeutics have improved survival but increased treatment-related cardiotoxicity, making early recognition imperative to guide safe therapeutic options.
Answers are grounded in this paper and cite their sources.
This review summarizes the role of cardiovascular imaging and biomarkers in the early identification of cardiotoxicity related to cancer therapeutics.
Innovations and discoveries in cancer therapeutics have improved survival rates in patients with various types of malignancies. At the same time, physicians are identifying an increased number of patients with treatment-related cardiotoxicity. It is imperative that physicians recognize early treatment-related adverse effects to determine the safest therapeutic options for patients with cancer. This manuscript evaluates the role of cardiovascular imaging and biomarkers in identifying cardiotoxicity trigged by various chemotherapeutic agents and summarizes expert consensus statements regarding cardiotoxicity monitoring.
No takes yet. Share an insight, caveat, or question.
Agha et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: